FDA Issues Nationwide Recall of Frontier Devices’ 14 mm Distraction Pins Over Unvalidated Shelf Life

Folsom Metal Products Faces Class II Recall Affecting Orthopedic Device Distribution Across 9 States

The U.S. Food and Drug Administration (FDA) has issued a Class II device recall concerning a widely distributed orthopedic surgical tool: the 14 mm Distraction Pin produced by Folsom Metal Products, Inc., under the Frontier Devices brand. The recall, officially posted on September 17, 2025, affects all lots distributed over a five-year period, from August 1, 2020 through July 30, 2025.

At the heart of the recall is a critical labeling failure—specifically, the inclusion of an expiration date that has not been validated through industry-standard testing protocols. The FDA's determination notes that the manufacturer did not provide sufficient data to support the claimed shelf life, raising concerns about the pin’s sterility and mechanical integrity over time.

The 14 mm Distraction Pin is a precision implant commonly used in orthopedic surgeries, particularly spinal and trauma procedures requiring controlled separation or stabilization of bone. Each unit is packaged sterile, labeled as “Rx Only,” and intended to remain in stock until surgical need arises.

However, an FDA inspection and subsequent internal review revealed that no validated testing had been completed to verify the stated expiration date printed on product packaging. Without scientifically verified stability data, the shelf life printed on thousands of units may be unreliable.

Though the recall is currently not linked to any reported injuries, infections, or device failures, the potential hazard of unknowingly using expired or unstable implants in orthopedic procedures prompted the agency to act. The recall is categorized as Class II, indicating a risk that could lead to temporary or medically reversible health consequences.

The affected product—REF 301.914S2, distributed in 10-unit double packs—was manufactured and shipped to hospitals, surgical centers, and distributors across nine U.S. states: Alabama, California, Florida, Georgia, Illinois, Maryland, Michigan, Pennsylvania, and Texas.

At a surface level, the issue may appear administrative. However, in the high-stakes environment of the operating room, labeling and documentation directly translate to clinical trust and patient safety. An unvalidated shelf life undermines that trust and may introduce unacceptable uncertainty about a device’s sterility, structural integrity, or chemical stability.

Sterile orthopedic implants are intended to remain contamination-free and mechanically intact for years if properly stored. A pin that degrades—even subtly—can fail to provide the support or fixation required in procedures such as vertebral distraction or joint reconstruction. Complications from such failures may include intraoperative delays, surgical site infections, or revision surgeries, particularly problematic in high-risk orthopedic populations like the elderly or immunocompromised.

Hospitals that stocked the product believing it had years of shelf life remaining must now reassess inventory and possibly quarantine or destroy functional but non-compliant stock—a disruption that could strain surgical schedules and supply budgets.

Moreover, for procurement and compliance teams, this case illustrates the risk of relying solely on manufacturer labeling without third-party verification or demand for validated shelf-life documentation, a step that may now become standard practice among more risk-averse institutions.

The recall has widespread implications across the surgical supply chain:

• Hospitals and Ambulatory Surgical Centers (ASCs): These facilities must immediately audit stockrooms and implant storage areas for affected devices. Units may appear “within shelf life,” but are now considered regulatory liabilities.

• Surgeons and OR teams: Need to be aware of the recall and ensure no affected pins are in surgical trays or instrument sets. Alternative validated devices should be sourced to avoid disruptions.

• Distributors and supply chain managers: Must notify downstream clients and ensure that returned or destroyed product is documented per FDA protocol.

• Frontier Devices / Folsom Metal Products: Will likely face further regulatory scrutiny and may be required to produce validated shelf-life studies, revise labeling, and possibly enhance quality assurance and stability testing protocols across all product lines.

• Regulatory bodies and accreditation agencies: This incident may prompt new guidance or inspection criteria regarding the documentation of shelf-life validation, especially for implants and sterile surgical components.

“What makes this recall notable is its silent risk—hospitals may have hundreds of these pins stored in good faith, assuming they’re sterile and structurally sound. But without validated shelf life, you lose certainty. That introduces a clinical variable that simply cannot be tolerated in orthopedic surgery,” according to industry analysis.

“This kind of recall reinforces that labeling isn’t a clerical issue—it’s a clinical promise,” the report concludes.

The recall notice outlines specific steps for affected institutions:

1. Quarantine all units from affected lots immediately—even if the expiration date appears to be in the future.

2. Complete the Medical Device Recall Response Acknowledgment Form, regardless of whether product is on hand.

3. Return affected inventory to Frontier Devices or destroy it per the provided Certificate of Destruction form.

4. If the facility redistributed the product, it must inform downstream users immediately and share recall documentation.

5. Transition to alternative distraction pins with FDA-verified expiration labeling and shelf-life validation.

The FDA encourages institutions to conduct a broader review of implant and device labeling practices, especially for products sourced from small or specialized manufacturers that may not maintain full-scope validation labs.

For surgical supply leaders, the Frontier Devices recall is a wake-up call:

• Reinforce supplier quality checks—particularly around labeling and shelf-life validation.

• Review implant procurement processes to ensure they align with FDA expectations on stability testing.

• Stay informed on all Class I and II device recalls, as early action can prevent surgical disruption and patient harm.

The full recall information, including affected lot codes and return instructions, can be accessed via the FDA Medical Device Recalls Database.